ACAlberto Fica C

Alberto Fica C

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alberto Fica C has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tuberculosis en el personal de salud del Servicio de Salud Metropolitano Sur de Santiago, Chile

    by Alberto Fica C, Paulina Ramonda C, M. Irene Jemenao P, Alejandra Zambrano G, Marcela Cifuentes D, Naldy Febré V, M. Cristina Ajenjo H, Luis Delpiano M, Alexis Diomedi P

    Tuberculosis in health care workers from a public health service in


    • 29 January 2009
      • Vol. 25  (6) , 419-27

    [Intravenous antimicrobial use among different hospital in Chile during 2005].

    by Alberto Fica C, Angela Cabello M, Chrystal Juliet L, Priscilla Prado D, Luis Bavestrello F

    Intravenous antimicrobial consumption has not been evaluated previously in Chile. In order to know this consumption (in DDD per 100 bed days), associated factors and antimicrobial control systems across the country, a questionnaire was sent to evaluate these features during 2005. A total of 29 public hospitals and private clinics answered this poll, 20 belonging to the public health system (69%). Only 48.1% declared to have an independent antimicrobial committee and 17.2% allowed unrestricted antimicrobial use. Glycopeptides and carbapenems were the most regulated compounds (75.9 and 82.8%, respectively). Antimicrobial controls systems were more frequently declared among public hospitals and only non-public hospitals permitted free use of antimicrobials. Global consumption reached 59.98 DDD per 100 bed-days, with beta-lactams representing 74.3% of this consume (44.57 DDD per 100), and cephalosporins 43% (25.78 DDD per 100). Chloramphenicol, penicillin G and cloxacillin use was significantly higher among public hospitals. The opposite was observed for imipenem-cilastatin, linezolid, cefuroxime and caspofungin with higher consumes observed among non-public hospitals. In a multivariate analysis, increased cefazolin use was independently associated with sites allowing unrestricted use, and ciprofloxacin consumption with non-public hospitals. Institutions with decreased susceptibility to imipenem-cilastatin among non-fermentative gram negative bacilli showed a higher use of this compound and linezolid consumption paralleled vancomycin-resistant enterococci prevalence. It is necessary to reinforce governmental regulations about antimicrobial use issued during 1999.


  • Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency

    by Alberto E. Fica, Nancy J. Abusada

    Three patients presented seizures during ertapenem therapy. They were classified as probably-related in 1 case and as possible-related in the others. Convulsions appeared after 1 week of therapy at usual doses with 1 or 2 events, and were observed only among patients with CNS disorders and renal insufficiency.


  • Open Access

    Emergencia de infecciones por Enterococcus sp resistente a vancomicina en un hospital universitario en Chile

    by Alberto Fica C, María Irene Jemenao P, Paola Bilbao V, Gloria Ruiz R, Andrea Sakurada Z, Edith Pérez de Arce O, Isabel Zúñiga B, Macarena Gompertz G


  • Open Access

    Colistín en infecciones nosocomiales por bacilos gramnegativos pan-resistentes

    by Alberto Fica C, Ignacio Céspedes J, Macarena Gompertz G, Mauricio Jalón V, Andrea Sakurada Z, Enzo Sáez L

    Emergence of panresistant gram negative bacilli has lead to the progressive reintroduction of intravenous colistin. To describe the clinical experience observed with this compound. A retrospective analysis was performed for all treatments lasting >/= 48 hours. Medical records were analyzed to obtain clinical parameters and microbiological data, evaluate clinical response and evolution until discharge. 24 treatments lasting >/= 48 hours were applied between June 2005 and September 2006. Intravenous colistin was indicated to treat cases of ventilator-associated (VA) pneumonia (n = 10; 41.7%), abscess or collections (12.5%), bloodstream infections, non-VA pneumonia or urinary tract infections (4.2% each one, respectively). Treatment was initiated on average at 3.2 days (+/- 2.85) from diagnosis of infection. All courses were microbiologically-guided, and involved P. aeruginosa or A. baumannii isolates. Susceptibility was evaluated by E-test in 11 isolates (MIC90 3.6 nicrog/mL, range 0.38 to 4 microg/mL). One isolate was resistant to colistin (9%). A favorable response was observed in 12 treatments (50%) with a relapse in 5 cases (41.7%). Being treated for pneumonia was the only factor associated to failure, (p = 0.04) Eradication was documented in 8 cases (33.3%) and persistence in 11 (45.8%). In 5 cases a microbiological follow-up was not available. Survival at time of discharge was 45.5%. (n = 10) None of the treatment courses was associated with nefrotoxicity. Intravenous colistin is a safe compound useful to treat various nosocomial infections due to pan-resistant gram negative bacilli. Nonetheless, its clinical efficacy is limited, especially among patients treated for nosocomial pneumonia.


  • Open Access

    Errores en la oportunidad y dosificación de aciclovir o valaciclovir en el tratamiento del herpes zoster

    by Alberto Fica C, Carla Jadue A, Luisa Donaire R

    Medical prescription errors are frequent in community settings and information exploring its magnitude during antiviral treatment of herpes zoster is scarce. A questionnaire was applied to 31 physicians working in hospital- or community-based settings in Santiago, Chile in order to characterize their dosing and timing preferences for aciclovir or valaciclovir prescriptions. Aciclovir was more often prescribed than valaciclovir (71.9 and 28.1%, respectively), but less than a third of prescription (27.3%) fulfilled the minimal aciclovir dosing and timing criteria for clinical efficacy (4 gr per day and <72 hours since rash initiation). The limited size of the simple prevented exploring factors linked to a misleading prescription. Appropriate knowledge on dosing and timing of aciclovir/valaciclovir therapy for herpes zoster was infrequent in a sample of physicians working in various clinical settings in Chile.

  • Open Access

    Bacteriemia por Campylobacter fetus subsp fetus en un paciente inmunosuprimido

    by Alberto Fica C, Víctor Illanes R, Andrea Sakurada Z, Mario Vidal C, M. Eugenia Valenzuela M


    • 23 November 2006
      • Vol. 23  (4) , 336-9

    [Bacteraemia due to Campylobacter fetus in an immune suppressed patient].

    by Alberto Fica C, Víctor Illanes R, Andrea Sakurada Z, Mario Vidal C, M Eugenia Valenzuela M

    We report a case of bacteraemia by Campylobacter fetus subsp. fetus in a 77 year-old woman with immunosuppression secondary to steroid use. Diagnosis was suspected by finding Gram negative curved rods in blood cultures taken after 4 days of a febrile illness without local findings. Diarrhea was not present. There was no consumption of undercooked meat or non-pasteurized milk and no contact with pets. The patient was treated with sulbactam-cefoperazone due to the coexistence of urinary tract infection by multiresistant E. coli. The outcome was favorable and albeit susceptibility was not assessed, quinolone resistance was presumed because illness appeared during ciprofloxacin prophylaxis for urinary tract infection. In contrast to C. jejuni infections, C. fetus infections are associated to debilitated or immunosuppressed patients, bacteraemia is predominant, diarrhea is rarely observed and disease is not self-limited.


  • Open Access

    Absceso cerebral: A propósito de una serie de 30 casos

    by Alberto Fica C, Patricio Bustos G, Gonzalo Miranda C

    A retrospective study was designed to ascertain the main clinical features of 30 patients admitted for brain abscess between 1989 and 2005. A contiguous source of infection was identified in 40% of cases, direct inoculation secondary to trauma or neurosurgery in 23,3%, and a distant source in 23,3%. Fever, headache and sensorial involvement were the main clinical manifestations. Temporal and frontal lesions were predominant. Microbiological information was available in only half of cases, prevailing polymicrobial and gram-positive bacterial infections. Most patients underwent surgical procedures (66.7%) and the rest received only medical therapy. During antimicrobial treatment, 6 patients (20%) suffered a serious adverse event that prompted discontinuation or change of therapy. Failure of treatment was observed in 40%, including 3 deaths (10%), non-programmed surgical drainage or reintervention (16.7%) and changes of the antimicrobial regimen (13.3%). Eight patients were discharged with sequels (26.7%), and during follow-up, 21% presented major events (death or brain abscess-related readmission).